SlidesetRespiDART 2018Abstract: Non-targeted diagnosis of multiple viral infections by means of shotgun metagenomic using deep sequencing (#104) | Slim Fourati, PhDView Slideset
SlidesetRespiDART 2018Abstract: Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV small hydrophobic protein (#105) | Genevieve WeirView Slideset
SlidesetRespiDART 2018Abstract: Risk factors for RSV severity in immunocompetent and immunocompromised adults presenting in an emergency department (#103) | Slim FouratiView Slideset
SlidesetRespiDART 20183D Human epithelial models to study respiratory virus pathogenesis | Samuel Constant, PhDView Slideset
SlidesetHIVRespiDART 2018Abstract: Structure-based prediction of influenza resistance mutations (#102) | Bryan CoxView Slideset
SlidesetHIVRespiDART 2018Abstract: SB 9200 is a novel broad-spectrum antiviral agent effective against both RSV and Flu (#101) | Diane SchmidtView Slideset
SlidesetHIVRespiDART 2018Difficulties and barriers in developing RSV polymerase inhibitors | Rachel Fearns, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Establishment of functional control and normalization of liver function in HBeAg negative chronic HBV infection following combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a.- Dr. A. VaillantView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Validation of a novel Transient Elastography for the measurement of liver fibrosis- Dr. J. DongView Slideset
VMVeronica MillerPhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Regulatory landscape for NASH- Veronica MillerView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells (not yet available)- Dr. E. ThomasView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years- Dr. R. HyerView Slideset
